Comparative effectiveness of early versus delayed metformin in the treatment of type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 108, Issue 1, 2015, Pages 170-178

  Romanelli, Robert J ^a   Chung, Sukyung ^a   Pu, Jia ^a   Nimbal, Vani ^a   Zhao, Beinan ^a   Palaniappan, Latha ^a,b  

^a PALO ALTO MEDICAL FOUNDATION RESEARCH INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Metformin; Pharmacotherapy; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; BODY MASS; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; EARLY TREATMENT; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROPENSITY SCORE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; THERAPY DELAY; TIME TO TREATMENT; UNITED STATES; BLOOD; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; TIME FACTOR;

BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84926181778     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.12.019     Document Type: Article

References (33)

1. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.
3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:854-865.
4. Bailey C.J., Del Prato S., Eddy D., Zinman B., Global Partnership for Effective Diabetes Management Earlier intervention in type 2 diabetes: the case for achieving early and sustained glycaemic control. Int J Clin Pract 2005, 59:1309-1316.
5. Pratley R.E. The early treatment of type 2 diabetes. Am J Med 2013, 126:S2-S9.
6. Klip A., Leiter L.A. Cellular mechanism of action of metformin. Diabetes Care 1990, 13:696-704.
7. Noury J., Nandeuil A. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. Diabete Metab 1991, 17:209-212.
8. Hannon T.S., Kirkman M.S., Patel Y.R., Considine R.V., Mather K.J. Profound defects in β-cell function in screen-detected type 2 diabetes are not improved with glucose-lowering treatment in the early diabetes prevention program (EDIP). Diabetes Metab Res Rev 2014, 30:767-776.
9. Garber A.J. Incretin effects on beta-cell function, replication, and mass: the human perspective. Diabetes Care 2011, 34(Suppl. 2):S258-S263.
10. Dixon J.B., Dixon A.F., O'Brien P.E. Improvements in insulin sensitivity and beta-cell function (HOMA) with weight loss in the severely obese. Homeostatic model assessment. Diabetic Med 2003, 20:127-134.
11. Pratley R.E., Weyer C. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 2001, 44:929-945.
12. Kahn S.E. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003, 46:3-19.
13. Stumvoll M., Goldstein B.J., van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005, 365:1333-1346.
14. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., Butler P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
15. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
16. Chung S., Zhao B., Lauderdale D., Linde R., Stafford R., Palaniappan L. Initiation of treatment for incident diabetes: evidence from the electronic health records in an ambulatory care setting. Primary Care Diabetes 2014, 9:23-30.
17. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
18. Quan H., Sundararajan V., Halfon P., Fong A., Burnand B., Luthi J.C., et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005, 43:1130-1139.
19. Raebel M.A., Ellis J.L., Schroeder E.B., O'Conner P.J., Segal J.B., Butler M., G, et al. Intensification of antihyperglycemic therapy among patients with incident diabetes: a Surveillance Prevention and Management of Diabetes Mellitus (SUPREME-DM) study. Pharmacoepidemiol Drug Saf 2014, 23:699-710.
20. Austin P.C. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011, 10:150-161.
21. Romanelli R.J., Jukes T., Segal J.B. Compliance after switching from branded to generic statins. Pharmacoepidemiol Drug Saf 2014, 23:1093-1100.
22. Garvey W.T., Olefsky J.M., Griffin J., Hamman R.F., Kolterman O.G. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985, 34:222-234.
23. Ilkova H., Glaser B., Tunckale A., Bagriacik N., Cerasi E. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997, 20:1353-1356.
24. Ryan E.A., Imes S., Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004, 27:1028-1032.
25. Weng J., Li Y., Zu W., Shi L., Zhang Q., Zhu D., et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008, 371:1753-1760.
26. Chen H.S., Wu T.E., Jap T.S., Hsiao L.C., Lee S.H., Lin H.D. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008, 31:1927-1932.
27. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
28. Harrison L.B., Adams-Huet B., Raskin P., Lingvay I. β-Cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care 2012, 35:1406-1412.
29. Nichols G.A., Conner C., Brown J.B. Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice. Curr Med Res Opin 2010, 26:2127-2135.
30. Brown J.B., Conner C., Nichols G.A. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 2010, 33:501-506.
31. Schmittdiel J.A., Uratsu C.S., Karter A.J., Heisler M., Subramanian U., Mangione C.M., et al. Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med 2008, 23:588-594.
32. Melikian C., White T.J., Vanderplas A., Dezii C.M., Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002, 24:460-467.
33. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977-986.